Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance

Kwang Yu Chang, Shan Yin Tsai, Shang Hung Chen, Hsiao Hui Tsou, Chia Jui Yen, Ko Jiunn Liu, Hsun Lang Fang, Hung Chang Wu, Bin Fay Chuang, Shao Wen Chou, Careen K. Tang, Shyun Yeu Liu, Pei Jung Lu, Ching Yu Yen, Jang Yang Chang

研究成果: 雜誌貢獻文章

17 引文 斯高帕斯(Scopus)

摘要

Background: Dysregulated epidermal growth factor receptor (EGFR)-phosphoinositide-3-kinase (PI3K)-AKT signaling is considered pivotal for oral cancer, and the pathway is a potential candidate for therapeutic targeting. Results: A total of 108 archival samples which were from surgically resected oral cancer were examined. Immunohistochemical staining showed the protein expression of membranous wild-type EGFR and cytoplasmic phosphorylated AKT was detected in 63.9% and 86.9% of the specimens, respectively. In 49.1% of the samples, no phosphatase and tensin homolog (PTEN) expression was detected. With regard to the EGFR variant III (EGFRvIII), 75.0% of the samples showed positive expression for moderate to severe staining, 31.5% of which had high expression levels. Real-time polymerase chain reaction assays for gene copy number assessment of PIK3CA revealed that 24.8% of the samples had alterations, and of EGFR showed that 49.0% had amplification. Direct sequencing of PIK3CA gene showed 2.3% of the samples had a hotspot point mutation. Statistical assessment showed the expression of the EGFRvIII correlated with the T classification and TNM stage. The Kaplan-Meier analyses for patient survival showed that the individual status of phosphorylated AKT and EGFRvIII led to significant differences in survival outcome. The multivariate analysis indicated that phosphorylated AKT, EGFRvIII expression and disease stage were patient survival determinants. Conclusions: Aberrations in the EGFR-PI3K-AKT pathway were frequently found in oral cancers. EGFRvIII and phosphorylated AKT were predictors for the patient survival and clinical outcome.
原文英語
文章編號43
期刊Journal of Biomedical Science
20
發行號1
DOIs
出版狀態已發佈 - 2013

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Pharmacology (medical)
  • Medicine(all)

指紋 深入研究「Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance」主題。共同形成了獨特的指紋。

  • 引用此

    Chang, K. Y., Tsai, S. Y., Chen, S. H., Tsou, H. H., Yen, C. J., Liu, K. J., Fang, H. L., Wu, H. C., Chuang, B. F., Chou, S. W., Tang, C. K., Liu, S. Y., Lu, P. J., Yen, C. Y., & Chang, J. Y. (2013). Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. Journal of Biomedical Science, 20(1), [43]. https://doi.org/10.1186/1423-0127-20-43